Are the Effects of Homeopathy Attributable to a Statistical Artefact? A Reanalysis of an Observational Study
Table 2
RTM adjusted effects after 12 months on MCS for various scenarios.
Sampling from …
… the general population*
… the actually diseased population*
… specifically diseased patients*
Disease (ICD-9)
Effect (95% CI)
Effect (95% CI)
Effect (95% CI)
All
0.12 (0.06 to 0.19)
0.0003
0.18 (0.14 to 0.23)
<0.0001
Headache (346.9 or 784.0)
0.26 (0.00 to 0.51)
0.0470
0.26 (0.09 to 0.44)
0.0037
Allergic rhinitis (477.9)
0.32 (0.12 to 0.51)
0.0014
0.33 (0.19 to 0.47)
<0.0001
0.35 (0.21 to 0.48)
<0.0001
Eczemas (692.9)
0.19 (−0.02 to 0.4)
0.0688
0.26 (0.11 to 0.40)
0.0007
Migraine (349.6)
0.14 (−0.09 to 0.37)
0.2416
0.19 (0.03 to 0.36)
0.0178
Sleep disturbances (780.5)
−0.33 (−0.70 to 0.05)
0.0904
−0.13 (−0.39 to 0.13)
0.3120
Allergies (995.3)
0.20 (−0.07 to 0.47)
0.1368
0.25 (0.07 to 0.44)
0.0082
0.27 (0.09 to 0.46)
0.0042
Depression (311.0)
−0.19 (−0.75 to 0.37)
0.4989
−0.03 (−0.41 to 0.36)
0.8938
Recurrent infections (796.9)
0.35 (0.07 to 0.62)
0.0139
0.36 (0.17 to 0.55)
0.0002
Atopic eczema (691.8)
0.17 (–0.13 to 0.46)
0.2640
0.22 (0.02 to 0.43)
0.0323
0.36 (0.21 to 0.52)
<0.0001
Anxiety (300.0)
0.24 (−0.19 to 0.67)
0.2707
0.29 (0.00 to 0.59)
0.0518
Hypertension (401.9)
−0.19 (−0.49 to 0.11)
0.2200
−0.07 (−0.28 to 0.14)
0.4978
−0.07 (−0.27 to 0.14)
0.5242
Recurrent sinusitis (473.9)
−0.04 (−0.45 to 0.37)
0.8514
0.08 (−0.19 to 0.35)
0.5621
Dysmenorrhea (625.3)
0.09 (−0.25 to 0.42)
0.6175
0.17 (−0.07 to 0.40)
0.1589
Low back pain (724.2)
0.16 (−0.14 to 0.46)
0.2914
0.20 (0.00 to 0.41)
0.0532
0.22 (0.02 to 0.42)
0.0003
Asthma (493.9)
0.20 (−0.06 to 0.46)
0.1231
0.25 (0.07 to 0.43)
0.0075
0.28 (0.13 to 0.42)
0.0003
Psoriasis (696.1)
−0.18 (−0.57 to 0.21)
0.3557
−0.03 (−0.30 to 0.24)
0.8475
0.17 (−0.03 to 0.38)
0.0961
As defined by the German health survey, which shows data for the general population, including diseased and healthy persons, for the subset of all actually diseased patients and for chronically ill patients suffering from specific diseases [14]; see Section 2.4.
